WO2024258949A3 - Immunosorbent nanoparticles and methods of using thereof - Google Patents

Immunosorbent nanoparticles and methods of using thereof Download PDF

Info

Publication number
WO2024258949A3
WO2024258949A3 PCT/US2024/033583 US2024033583W WO2024258949A3 WO 2024258949 A3 WO2024258949 A3 WO 2024258949A3 US 2024033583 W US2024033583 W US 2024033583W WO 2024258949 A3 WO2024258949 A3 WO 2024258949A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunosorbent
nanoparticles
methods
microglobulin
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033583
Other languages
French (fr)
Other versions
WO2024258949A2 (en
Inventor
Paul Moroz
Todd Yeates
Justin Miller
Roger CASTELLS-GRAELLS
Mark Aubrey ARBING
Aldo MUNOZ
Brian Thuan NGUYEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to AU2024303275A priority Critical patent/AU2024303275A1/en
Priority to EP24824061.6A priority patent/EP4727598A2/en
Publication of WO2024258949A2 publication Critical patent/WO2024258949A2/en
Publication of WO2024258949A3 publication Critical patent/WO2024258949A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are immunosorbent nanoparticles, devices, and methods for selective removal of a target protein such as beta-2 microglobulin (B2M) from a liquid such as blood.
PCT/US2024/033583 2023-06-16 2024-06-12 Immunosorbent nanoparticles and methods of using thereof Ceased WO2024258949A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024303275A AU2024303275A1 (en) 2023-06-16 2024-06-12 Immunosorbent nanoparticles and methods of using thereof
EP24824061.6A EP4727598A2 (en) 2023-06-16 2024-06-12 Immunosorbent nanoparticles and methods of using thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508514P 2023-06-16 2023-06-16
US63/508,514 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024258949A2 WO2024258949A2 (en) 2024-12-19
WO2024258949A3 true WO2024258949A3 (en) 2025-02-13

Family

ID=93852878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033583 Ceased WO2024258949A2 (en) 2023-06-16 2024-06-12 Immunosorbent nanoparticles and methods of using thereof

Country Status (3)

Country Link
EP (1) EP4727598A2 (en)
AU (1) AU2024303275A1 (en)
WO (1) WO2024258949A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002278A1 (en) * 1994-07-18 1996-02-01 Laboratoires Upsa Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies
US20110020311A1 (en) * 2009-07-27 2011-01-27 James Layne Boucher Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy
US20130118979A1 (en) * 2007-12-03 2013-05-16 Hepa Wash Gmbh Dialysate Regeneration Unit
US20150356240A1 (en) * 2013-02-07 2015-12-10 University of Washington Through it's Center for Commercialization Self-Assembling Protein Nanostructures
US20220062430A1 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Self Assembling Protein Nanoparticles as Carrier Molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002278A1 (en) * 1994-07-18 1996-02-01 Laboratoires Upsa Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies
US20130118979A1 (en) * 2007-12-03 2013-05-16 Hepa Wash Gmbh Dialysate Regeneration Unit
US20110020311A1 (en) * 2009-07-27 2011-01-27 James Layne Boucher Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy
US20150356240A1 (en) * 2013-02-07 2015-12-10 University of Washington Through it's Center for Commercialization Self-Assembling Protein Nanostructures
US20220062430A1 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Self Assembling Protein Nanoparticles as Carrier Molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCNULTY MATTHEW J., SCHWARTZ ANTON, DELZIO JESSE, KARUPPANAN KALIMUTHU, JACOBSON AARON, HART OLIVIA, DANDEKAR ABHAYA, GIRITCH ANAT: "Affinity Sedimentation and Magnetic Separation With Plant-Made Immunosorbent Nanoparticles for Therapeutic Protein Purification", FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 10, CH , XP093280477, ISSN: 2296-4185, DOI: 10.3389/fbioe.2022.865481 *

Also Published As

Publication number Publication date
WO2024258949A2 (en) 2024-12-19
EP4727598A2 (en) 2026-04-22
AU2024303275A1 (en) 2026-01-15

Similar Documents

Publication Publication Date Title
WO2004113922A3 (en) System and method employing photokinetic techniques in cell biology imaging applications
SE0201317D0 (en) Method and device for the removal of partially protein bound substances
WO2022175414A8 (en) Multispecific anti-tcr delta variable 1 antibodies
EP4632066A3 (en) Class ii, type ii crispr systems
WO2005000095A3 (en) Isoforms of brain natriuretic peptide
WO2000059380A3 (en) Apparatus and methods for anastomosis
TW200624173A (en) Process and apparatus for improved methods for making vinyl acetate monomer (vam)
NO975511L (en) Non-ionic aqueous polyurethane dispersions and methods of preparation
WO2024258949A3 (en) Immunosorbent nanoparticles and methods of using thereof
EP4273161A4 (en) Protein containing heterodimer antibody fc, and preparation method therefor
WO2005118885A3 (en) Methods and apparatus for detection of viral infection
WO2023146922A3 (en) Methods for human leukocyte antigen typing and phasing
WO2006039555A3 (en) Device and method for counteracting hypotension
MX2008001861A (en) Emergency disconnection system.
WO2021191674A3 (en) Methods for screening of anti-virus reagent using organoids
EP4115446A4 (en) System, method, and target for wafer alignment
WO2006106400A3 (en) Capsules containing seminal material for artificial insemination
WO2022198052A3 (en) High-throughput microemulsification membrane
WO2004011401A3 (en) Method for making biochips
WO2023196598A3 (en) Anti-mica/b antibodies and uses thereof
GB2605887A (en) Controlled chemical synthesis using polymer substrates and nanofluidic separation systems
CA3297377A1 (en) Anti-a-beta protein antibodies, methods and uses thereof
NO20055948L (en) Purification of HER-2 variants
CA3286430A1 (en) Methods and reagents for synthesizing haloaldehydes, and uses thereof
NZ604943A (en) Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024303275

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024303275

Country of ref document: AU

Date of ref document: 20240612

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024824061

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024824061

Country of ref document: EP

Effective date: 20260116

ENP Entry into the national phase

Ref document number: 2024824061

Country of ref document: EP

Effective date: 20260116

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824061

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2024824061

Country of ref document: EP